Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Voranigo

(voh-rah-NEE-goh)
A drug used to treat adults and children aged 12 years and older with grade 2 astrocytoma or oligodendroglioma (types of brain tumors) that has an abnormal IDH1 or IDH2 gene. It is used in patients who had a biopsy or surgery to remove the tumor. It is also being studied in the treatment of other types of cancer. Voranigo blocks the proteins made by the mutated IDH1 and IDH2 genes, which may help keep cancer cells from growing. It is a type of enzyme inhibitor and a type of targeted therapy. Also called vorasidenib citrate.
More Information
Search NCI's Dictionary of Cancer Terms